Vertebra

Hyprevention Becomes a U.S. Based Company, Focusing Commercial Sales Operations in the U.S.

Retrieved on: 
Wednesday, April 3, 2024
Oncology, Health, Medical Devices, Neurology, Hospitals, Surgery, Managed Care, Growth, Physician, Patient, Vertebra, Cancer, Osteoporosis, Vertebral compression fracture

Hyprevention Inc. ("Hyprevention"), a medtech company, announced today that it incorporated in Delaware, becoming the new parent company of the group previously established in France in 2010.

Key Points: 
  • Hyprevention Inc. ("Hyprevention"), a medtech company, announced today that it incorporated in Delaware, becoming the new parent company of the group previously established in France in 2010.
  • In addition to establishing Hyprevention as a U.S. based product, the company appointed Kathryn Larson to the Board of Directors.
  • "Kathryn brings a wealth of commercial knowledge and experience to Hyprevention, including her most recent success with Vertiflex (acquired by Boston Scientific Inc).
  • Hyprevention investor Yellowstone Holdings led the additional funding in early 2024 to support the company in its U.S. transition.

Relievant Medsystems Announces Positive Coverage Policy from Humana for the Intracept Procedure

Retrieved on: 
Monday, November 13, 2023
Brain, Safety, Acceleration, Cigna, Patient, Short-term energy-relieving behavior, FDA, Vertebra, MD, Diagnosis, Pain, Humana, BVN, Physician, Inflammation, Health insurance, Medical imaging

MINNEAPOLIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems , a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back pain, today announced that Humana has published a favorable coverage policy for the Intracept® Procedure.

Key Points: 
  • MINNEAPOLIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems , a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back pain, today announced that Humana has published a favorable coverage policy for the Intracept® Procedure.
  • Humana is now the third national payer to issue a positive coverage policy for the Intracept Procedure in 2023.
  • Cigna Healthcare and Anthem Blue Cross Blue Shield also published positive coverage policies that went into effect in June and September, respectively.
  • More than 15,000 patients have been treated with Relievant Medsystems’ minimally invasive Intracept Procedure, the only FDA-cleared treatment for chronic vertebrogenic low back pain.

MiRus Announces FDA 510(k) Clearance for Molybdenum-Rhenium (MoRe®) Low Profile Anterior Cervical and Lateral Lumbar Plating Systems

Retrieved on: 
Wednesday, October 18, 2023
FDA, ACP, MD, Spine, Vertebra, Catherine Disher, Dysphagia, Patient, ACDF, Risk, Surgeon, Integration, Rhenium, Birth control

ATLANTA, Oct. 18, 2023 /PRNewswire/ -- MiRus® announced  that it has received FDA 510(k) clearance of the CYGNUS™ MoRe® Anterior Cervical Plate and MiRus® 3DR™ Lateral Lumbar Interbody Fusion System with Integrated MoRe®  plate fixation, both being the narrowest and thinnest plating system amongst all plates on the global spine market.

Key Points: 
  • ATLANTA, Oct. 18, 2023 /PRNewswire/ -- MiRus® announced  that it has received FDA 510(k) clearance of the CYGNUS™ MoRe® Anterior Cervical Plate and MiRus® 3DR™ Lateral Lumbar Interbody Fusion System with Integrated MoRe®  plate fixation, both being the narrowest and thinnest plating system amongst all plates on the global spine market.
  • MoRe®, a proprietary molybdenum rhenium superalloy for medical implants, provides an unprecedented combination of strength, ductility, durability, and biological safety.
  • The proprietary molybdenum-rhenium alloy used in the Integrated MoRe® lateral  plate allows for a dramatically smaller footprint of tapered 2mm thickness, without sacrificing performance.
  • The Integrated MoRe® Lateral  Plate was awarded the 2023  Spine Technology Award for its clinical relevance, clinical problem solving and  likelihood of improving patient outcomes.

Relievant Medsystems Announces Positive Coverage Policy for the Intracept Procedure from Anthem Blue Cross and Blue Shield

Retrieved on: 
Tuesday, October 3, 2023
Short-term energy-relieving behavior, Policy, Brain, Elevance Health, Inflammation, Cigna, Pain, Vertebra, Blue Shield, MD, Patient, BVN, Physician, Diagnosis, FDA, News, Safety, Health insurance, Medical imaging

MINNEAPOLIS, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems , a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back pain, today announced that Anthem Blue Cross and Blue Shield has established favorable coverage for the Intracept® Procedure.

Key Points: 
  • MINNEAPOLIS, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems , a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back pain, today announced that Anthem Blue Cross and Blue Shield has established favorable coverage for the Intracept® Procedure.
  • The favorable coverage policy from Anthem Blue Cross Blue Shield is the latest in a series of recent positive coverage determinations for the Intracept Procedure.
  • “We continue to educate payers on the robust clinical evidence supporting the efficacy, safety and durability of the Intracept Procedure.
  • The decision from Anthem Blue Cross and Blue Shield is an important step in expanding patient and physician access to this proven treatment,” said Tyler Binney, President and CEO of Relievant Medsystems.

Safe Orthopaedics announces the publication of a biomechanical study on Sycamore

Retrieved on: 
Tuesday, August 8, 2023
Surgeon, CET, Vertebral compression fracture, Osteoporosis, Vertebra, Professor, Augmented fifth, Journal, Patient, Fracture, Bone fracture, Dentistry, Adhesive, Spine, Sycamore, Vertebral augmentation

Éragny-sur-Oise, Fleurieux sur l’Arbresle, France, le 07 août 2023 à 17h30 CET – Safe (FR001400F1V2 – ALSAF), french group specialized in the design, manufacturing and distribution of ready-to-use medical devices for Spine surgeries, especially safe for vertebral fracture treated in emergency, announces the publication of a biomechanical study of Sycamore and over 160 patients treated with Sycamore.

Key Points: 
  • Éragny-sur-Oise, Fleurieux sur l’Arbresle, France, le 07 août 2023 à 17h30 CET – Safe (FR001400F1V2 – ALSAF), french group specialized in the design, manufacturing and distribution of ready-to-use medical devices for Spine surgeries, especially safe for vertebral fracture treated in emergency, announces the publication of a biomechanical study of Sycamore and over 160 patients treated with Sycamore.
  • Leaded by Professor Jean-Charles Le Huec, the study compares the biomechanical behavior of vertebrae treated by “Dowelplasty”, a new surgical technique using a pedicle anchored device Sycamore (commercial name by Safe Orthopedics) with a traditional kyphoplasty system.
  • The study is published in the Journal of Experimental Orthopedics.
  • In comparison with the Kyphoplasty, Sycamore shows a significant increase of the compression strength (373 N ; IC à 95% ; – 331 N versus – 1076 N for Sycamore).

Relievant Medsystems Announces Favorable Coverage Policy from Cigna Healthcare for the Intracept Procedure

Retrieved on: 
Tuesday, June 20, 2023
Insurance, Form 1095, Short-term energy-relieving behavior, Brain, Inflammation, Cigna, LCD, Pain, Medicare, DO, MAC, Vertebra, Patient, BVN, Diagnosis, FDA, Health insurance, Medical imaging

MINNEAPOLIS, June 20, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems , a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back pain, announced today that Cigna Healthcare, a health benefits provider for 19 million Americans, has established national coverage for the Intracept® Procedure.

Key Points: 
  • MINNEAPOLIS, June 20, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems , a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back pain, announced today that Cigna Healthcare, a health benefits provider for 19 million Americans, has established national coverage for the Intracept® Procedure.
  • “This positive coverage determination from Cigna Healthcare, one of the country’s leading health benefit providers, is vastly impactful in increasing patient and physician access to our proven treatment for vertebrogenic pain,” said Tyler Binney, President and CEO of Relievant Medsystems.
  • More than 10,000 patients have now been treated with Relievant Medsystems’ minimally invasive Intracept Procedure, the only FDA-cleared treatment for chronic vertebrogenic low back pain.
  • The Intracept Procedure is supported by strong scientific evidence, including two Level I randomized clinical trials and data showing improvements are sustained more than five years post-procedure.

Snap Inc. Unveils ARES to Bring Power of Its Augmented Reality to Enterprises

Retrieved on: 
Thursday, March 23, 2023
Content Marketing, Communications, Technology, Apps, Applications, Fashion, Mobile, Wireless, Retail, Other Technology, Augmented reality, Inc., Stereoscopy, William Goodred, ARES, Forma, Game try, Snap Inc., Machine learning, Princess, AR, Creative industries, Online shopping, Vertebra, Q2

Snap Inc. today unveiled AR Enterprise Services (ARES), a new enterprise solution to enable businesses to integrate Snap's Augmented Reality (AR) into their owned and operated channels with ease and at scale.

Key Points: 
  • Snap Inc. today unveiled AR Enterprise Services (ARES), a new enterprise solution to enable businesses to integrate Snap's Augmented Reality (AR) into their owned and operated channels with ease and at scale.
  • ARES’ inaugural offering is for retail, and among the first group of customers are Goodr, Princess Polly, and Gobi Cashmere.
  • Each of these companies have been using various products from Fit Finder to AR Try-On, which are features that make up our new Shopping Suite.
  • ARES’ Shopping Suite will be widely available to customers in Q2 and includes AR shopping for apparel, footwear, and accessories.

Relievant Medsystems Announces Updated Policy Statement and Guideline for Basivertebral Nerve Ablation from the International Society for the Advancement of Spine Surgery

Retrieved on: 
Tuesday, November 8, 2022
Quality of life, GLOBE, Vertebra, International Society, Adoption, Society, Diagnosis, ASPN, BVN, Brain, Literature review, Patient, Canadian International Council, Time, Policy, Inflammation, Awareness, Pain, Treatment, CEO, Intraosseous infusion, FDA, Dentistry, Neuroscience

The ISASS policy recommends intraosseous BVN ablation as the most successful way to address vertebrogenic chronic low back pain.

Key Points: 
  • The ISASS policy recommends intraosseous BVN ablation as the most successful way to address vertebrogenic chronic low back pain.
  • This update follows the September publication of Best Practice Guidelines on the Diagnosis and Treatment of Vertebrogenic Low Back Pain with BVN Ablation from the American Society of Pain and Neuroscience (ASPN) and demonstrates additional society support for BVN ablation.
  • Relievant Medsystems minimally invasive Intracept Procedure is the only FDA-cleared treatment for chronic vertebrogenic low back pain.
  • For more information about Relievant Medsystems and the Intracept Procedure, visit www.relievant.com .

Relievant Medsystems Receives Most Promising New Product Award for the Intracept Procedure at the 27th Annual Phoenix Conference

Retrieved on: 
Wednesday, October 26, 2022
Diagnosis, Conference, Short-term energy-relieving behavior, Brain, CEO, Adoption, New product development, Patient, Inflammation, Physician, Phoenix, Technology, Vertebra, Quality of life, GLOBE, FDA, Time, Pain, Dentistry

We are honored to receive this prestigious award from the medical device leaders and innovators at the highly-respected Phoenix Conference, said Tyler Binney, President and CEO of Relievant Medsystems.

Key Points: 
  • We are honored to receive this prestigious award from the medical device leaders and innovators at the highly-respected Phoenix Conference, said Tyler Binney, President and CEO of Relievant Medsystems.
  • Across level 1 randomized clinical trials and meta-analyses, the Intracept Procedure has demonstrated significant improvements in pain and function for patients with chronic vertebrogenic low back pain.
  • Relievant Medsystems minimally invasive Intracept Procedure is the only FDA-cleared treatment for chronic vertebrogenic low back pain.
  • For more information about Relievant Medsystems and the Intracept Procedure, visit www.relievant.com .

Relievant Medsystems Announces Publication of ASPN Guidelines on the Diagnosis and Treatment of Vertebrogenic Low Back Pain with Basivertebral Nerve Ablation

Retrieved on: 
Tuesday, September 20, 2022
Inflammation, Time, Safety, Vertebra, Journal, USPSTF, FDA, Brain, Journal of Pain Research, University of Kansas Health System, Society, Treatment, University, Patient, BVN, Physician, CEO, Technology, Pain, Quality of life, Diagnosis, ASPN, GLOBE, Dentistry, Medical imaging

Following the publication of these guidelines, physicians can confidently recommend BVN ablation as the first treatment for patients presenting with anterior column pain and Modic changes* after failing six months of conservative care.

Key Points: 
  • Following the publication of these guidelines, physicians can confidently recommend BVN ablation as the first treatment for patients presenting with anterior column pain and Modic changes* after failing six months of conservative care.
  • The ASPN best practice guidelines are reflective of a marked shift in how we treat and provide life-changing, long-lasting improvement for patients with chronic vertebrogenic low back pain.
  • Relievant Medsystems minimally invasive Intracept Procedure is the only FDA-cleared treatment for chronic vertebrogenic low back pain.
  • The technology uses targeted radiofrequency energy to stop the basivertebral nerve from transmitting pain signals to the brain.